STOCK TITAN

ExodusPoint Discloses 5.05% Then 4.75% Position in ALT5 Sigma (Schedule 13G)

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G

Rhea-AI Filing Summary

Schedule 13G filed jointly by ExodusPoint entities and two individuals reports beneficial ownership of shares of ALT5 Sigma Corp common stock. As of August 11, 2025 the Reporting Persons were deemed to beneficially own 6,200,000 shares (about 5.05% of the class) held by ExodusPoint Partners Master Fund, LP; as of the filing date they report they may be deemed to own 5,856,700 shares (about 4.75%). The reporting group has no sole voting or dispositive power and reports shared voting and dispositive power over 5,856,700 shares. The filing includes a Joint Filing Agreement as Exhibit 99.1 and certifications that the holdings are not for purposes of changing control.

Positive

  • Transparent joint disclosure by the investment manager, GP and principals with Exhibit 99.1
  • Clear numeric detail on shares and percentage (6,200,000 at 5.05% on Aug 11, 2025; 5,856,700 at 4.75% as of filing)

Negative

  • Reported stake declined from ~5.05% to ~4.75%, reducing the reported ownership below the 5% threshold

Insights

TL;DR: ExodusPoint disclosed a stake just above 5% that later fell below 5%, signaling a non-controlling institutional position.

The Schedule 13G shows an institutional investor (ExodusPoint Master Fund) initially holding approximately 5.05% of ALT5 Sigma Corp then reporting a current position of ~4.75%. The report clarifies that voting and dispositive powers are shared, not sole, and the holders state the position is passive (not intended to influence control). For investors, the filing documents meaningful but non-controlling exposure concentrated in one fund vehicle and reflects routine reporting and joint filing governance.

TL;DR: Joint filing and Exhibit 99.1 indicate coordinated disclosure; ownership below 5% removes certain Section 13d implications.

The filing structure—ExodusPoint Capital Management, ExodusPoint Capital Partners, and two individuals filing jointly—follows Rule 13d-1(k) practices and supplies required certifications. The change from ~5.05% to ~4.75% is material for reporting classification: crossing below 5% typically changes obligations under Schedule 13D timing and disclosure expectations. The statement that holdings are not for the purpose of influencing control is a standard certification but legally important for classification.






Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)






SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G



ExodusPoint Capital Management, LP
Signature:/s/ Timothy Cruise
Name/Title:Timothy Cruise, Authorized Signatory
Date:08/18/2025
ExodusPoint Capital Partners GP, LLC
Signature:/s/ Timothy Cruise
Name/Title:Timothy Cruise, Authorized Signatory
Date:08/18/2025
Michael Gelband
Signature:/s/ Michael Gelband
Name/Title:Michael Gelband
Date:08/18/2025
Hyung Lee
Signature:/s/ Hyung Lee
Name/Title:Hyung Lee
Date:08/18/2025
Exhibit Information

Exhibit 1: Joint Filing Agreement, dated August 18, 2025

FAQ

What stake did ExodusPoint report in ALT5 Sigma Corp (CUSIP 47089W104)?

As of August 11, 2025 they were deemed to beneficially own 6,200,000 shares (~5.05%); the filing states they may now be deemed to own 5,856,700 shares (~4.75%).

Who are the reporting persons on this Schedule 13G for ALT5 Sigma?

The filing is by ExodusPoint Capital Management, LP, ExodusPoint Capital Partners GP, LLC, and individuals Michael Gelband and Hyung Lee.

Do the reporting persons claim voting or dispositive control over the shares?

They report 0 sole voting or dispositive power and shared voting and dispositive power over 5,856,700 shares.

Does the filing indicate the position is intended to influence control of ALT5 Sigma?

No; the certification states the securities were not acquired and are not held for the purpose of changing or influencing control.

Where is the issuer headquartered according to the filing?

The issuer's principal executive offices are listed at 325 E. Warm Springs Road, Suite 102, Las Vegas, Nevada 89119.
JanOne Inc.

NASDAQ:JAN

JAN Rankings

JAN Latest News

JAN Latest SEC Filings

JAN Stock Data

27.14M
12.17M
Household Appliance Stores
Pharmaceutical Preparations
Link
US
LAS VEGAS